DT2216

About Dialectic Therapeutics

Dialectic Therapeutics is a private, preclinical-to-clinical stage biotech developing novel cancer therapies based on its Antiapoptotic Protein Targeted Degradation (APTaD™) platform. Its lead candidate, DT2216, is a BCL-XL degrader currently in Phase 1/2 trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer. The company is led by a team with strong scientific, clinical, and commercial biotech experience, including co-founder John Harkey Jr., who previously co-founded and led AveXis to an $8.7bn acquisition. Dialectic operates as a virtual company, leveraging research partnerships with academic institutions.

About Dialectic Therapeutics

Dialectic Therapeutics is a private, preclinical-to-clinical stage biotech developing novel cancer therapies based on its Antiapoptotic Protein Targeted Degradation (APTaD™) platform. Its lead candidate, DT2216, is a BCL-XL degrader currently in Phase 1/2 trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer. The company is led by a team with strong scientific, clinical, and commercial biotech experience, including co-founder John Harkey Jr., who previously co-founded and led AveXis to an $8.7bn acquisition. Dialectic operates as a virtual company, leveraging research partnerships with academic institutions.

Therapeutic Areas